InflaRx (IFRX) Other financing activities (2018 - 2025)
InflaRx's (IFRX) quarterly Other financing activities came in at $13.6 million in Q1 2025, up 10941.61% quarter-over-quarter from $123044.1 in Q2 2023.
Powered by 
Analysis
InflaRx (IFRX) Other financing activities (2018 - 2025) Analysis & Trends
InflaRx has disclosed Other financing activities across 4 years of filings, most recently posting $13.6 million for Q1 2025.
- In Q1 2025, Other financing activities changed N/A year-over-year to $13.6 million; the TTM figure through Dec 2025 stood at $13.6 million (changed N/A YoY), while the FY2025 annual figure was $14.6 million, changed N/A from the prior year.
- Other financing activities came in at $13.6 million for Q1 2025 at InflaRx, up from $123044.1 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $13.6 million in Q1 2025 to a low of $58168.6 in Q4 2021.
- Average Other financing activities over 3 years is $3.0 million, with a median of $133037.5 recorded in 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 13.59 Mn |
| Jun 30, 2023 | 123,044.10 |
| Mar 31, 2023 | 133,037.50 |
| Dec 31, 2021 | 58,168.63 |
| Mar 31, 2021 | 1.16 Mn |
| Dec 31, 2018 | 377.80 |